$PFE News
Last published 1d ago
- 1d agoPFEPfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity ProgramBusiness WireNEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chro ...
- 2d agoPFEPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ConferenceBusiness WireNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026 at 9:00 a.m. GMT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing ...
- 1w agoPFEPFIZER INC - EX-99Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoPFENKEPfizer hikes full-year outlook on new product growth, taps company veteran as new CFOCNBCPfizer announced that Cecile Guegan, who has held various leadership roles at the company over the last 20 years, stepped in as CFO this month.
- 1w agoGMABABBVMRKJNJ+4A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBCGenmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- 1w ago.IXIC.SPX.DJIAAPL+9Cramer’s week ahead: Expect more volatility as tech earnings, midterms loomCNBCInvestors await earnings from Apple, AMD, and other major companies, as well as the midterm elections and the monthly jobs report.
- 2w agoPFEPfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple MyelomaBusiness WireIn the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide, with median PFS
- 2w agoPFEPfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment SettingBusiness WireTALZENNA plus XTANDI is now approved for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, offering a potential new standard of care earlier in the course of
- 2w agoGTBPMRNAIOVAGMAB+1Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment MarketGlobeNewswireNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are
- 2w agoPFEApproval of Talzenna, Nda #211651 (Efficacy)FDA Approved DrugsApproval Date: 10/26/2026; Drug Name: Talzenna, Nda #211651; Active Ingredients: TALAZOPARIB TOSYLATE; Company: Pfizer; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 211651
- 2w agoPFEApproval of Talzenna, Nda #217439 (Efficacy)FDA Approved DrugsApproval Date: 10/26/2026; Drug Name: Talzenna, Nda #217439; Active Ingredients: TALAZOPARIB TOSYLATE; Company: Pfizer; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 217439
- 2w agoPFEPfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026Business WireInvestigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal
- 3w agoPFEApproval of Zyvox, Nda #021132 (Labeling)FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Zyvox, Nda #021132; Active Ingredients: LINEZOLID; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021132
- 3w agoPFEApproval of Zyvox, Nda #021131 (Labeling)FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Zyvox, Nda #021131; Active Ingredients: LINEZOLID; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021131
- 3w agoPFEApproval of Zyvox, Nda #021130 (Labeling)FDA Approved DrugsApproval Date: 10/23/2026; Drug Name: Zyvox, Nda #021130; Active Ingredients: LINEZOLID; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021130
- 3w agoPFENTHIAVTRLLYHealthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth ChapterGlobeNewswireDENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE:PFE) is drawing renewed attention to
- 4w agoPFEPfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026Business WireData from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV Pfizer Inc. (NYSE:PFE) will present data from more than 50 company-sponsored,
- 1mo agoPFEApproval of Azulfidine En-tabs, Nda #007073 (Labeling)FDA Approved DrugsApproval Date: 10/14/2026; Drug Name: Azulfidine En-tabs, Nda #007073; Active Ingredients: SULFASALAZINE; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 007073
- 1mo agoPFEApproval of Azulfidine, Nda #007073 (Labeling)FDA Approved DrugsApproval Date: 10/14/2026; Drug Name: Azulfidine, Nda #007073; Active Ingredients: SULFASALAZINE; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 007073
- 1mo agoPFEPfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerBusiness WireTUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option Pfizer Inc. (NYSE:PFE) today
- 1mo agoPFEAstellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026PR NewswireAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that 21 abstracts from its oncology portfolio will be...
- 1mo agoPFEPfizer Declares Fourth-Quarter 2026 DividendBusiness WirePfizer Board of Directors approves fourth-quarter 2026 cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the
- 1mo agoPFEPfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoBusiness WireLITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a potential new oral
- 1mo agoPFEPfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis StudyBusiness WireStudy met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific antibody Pfizer
- 1mo agoPFEApproval of Ruxience, Bla #761103FDA Approved DrugsApproval Date: 09/29/2026; Drug Name: Ruxience, Bla #761103; Active Ingredients: RITUXIMAB-PVVR; Company: Pfizer Inc; Submission Status: Approval; Application Number: 761103
- 1mo agoPFEPfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMOBusiness WireData across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF’4404) Pfizer Inc.
- 1mo agoOPENAI.FGPFECMGAAL+1Cyber startup Island hits $6.4 billion valuation in new round as AI attacks fuel spending waveCNBCIsland faces an increasingly competitive cybersecurity market fueled by demand for agentic Ai defenses
- 1mo agoPFEPfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with AnalystsBusiness WirePfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 3, 2026. The purpose of the call is
- 1mo agoPFEApproval of Xeljanz Xr, Nda #208246 (Labeling)FDA Approved DrugsApproval Date: 09/16/2026; Drug Name: Xeljanz Xr, Nda #208246; Active Ingredients: TOFACITINIB CITRATE; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 208246
- 1mo agoPFEApproval of Xeljanz, Nda #213082 (Labeling)FDA Approved DrugsApproval Date: 09/16/2026; Drug Name: Xeljanz, Nda #213082; Active Ingredients: TOFACITINIB CITRATE; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 213082
- 1mo agoPFEPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferenceBusiness WirePfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S.
- 1mo agoNNVCGILDMRNAPFE+1A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatGlobeNewswireNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can
- 1mo agoPFEPFIZERMorgan Stanley 24th Annual Global Healthcare Conference - PFIZER INCEarnings Call TranscriptsGreat. Good morning. Thanks for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharm Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com backsl
- 2mo agoPFEPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferenceBusiness WirePfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare
- 2mo agoPFEApproval of Cibinqo, Nda #213871 (Labeling)FDA Approved DrugsApproval Date: 09/02/2026; Drug Name: Cibinqo, Nda #213871; Active Ingredients: ABROCITINIB; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 213871
- 2mo agoPFEApproval of Cleocin Hydrochloride, Nda #050162 (Labeling)FDA Approved DrugsApproval Date: 09/01/2026; Drug Name: Cleocin Hydrochloride, Nda #050162; Active Ingredients: CLINDAMYCIN HYDROCHLORIDE; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 050162
- 2mo agoNVOPFELLYTrump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakersCNBCThe string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.
- 2mo agoPFEBNTXPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineBusiness Wire2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to this season’s
- 2mo agoBNTXPFEPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineGlobeNewswire2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s
- 2mo agoPFEApproval of Zavzpret, Nda #216386 (Labeling)FDA Approved DrugsApproval Date: 08/17/2026; Drug Name: Zavzpret, Nda #216386; Active Ingredients: ZAVEGEPANT HYDROCHLORIDE; Company: Pfizer; Submission Status: Approval; Submission Classification: Labeling; Application Number: 216386
- 3mo agoPFEVALNPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencyGlobeNewswireSubmission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the
- 3mo agoPFEVALNPARIS:VLAPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencyBusiness WireSubmission based on favorable efficacy and safety results from Phase 3 VALOR trial Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the European Medicines Agency (EMA) has
- 3mo agoCATMCDPFEADIG+2NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-OffPR NewswireThe New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for ...
- 3mo agoPFEPfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid productsCNBCPfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.
- 3mo agoPFEPfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue GuidanceBusiness WireFocused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months Announces
- 3mo ago.SPX.IXIC.DJIGOOGL+35U.S.-Iran talks, OpenAI's Hugging Face hack, Best Buy's new CEO and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 3mo agoPFEPfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental VitiligoBusiness WireTwo pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 LITFULO was
- 3mo agoBNTXPFEEuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionGlobeNewswireData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the
- 3mo agoPFEBNTXEuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionBusiness WireData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the
- 3mo agoPFEFDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate CancerBusiness WireSupplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% improvement in